RxDoctor Payments Data

Michael Cheng, MD

Family Medicine · Dallas, TXNPI 1750365581

Payments from drug & device makers

$3,962in general payments, 2019–2025

Across 242 payments — averaging $16.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$537
  • Pfizer$505
  • Merck$435
  • Lilly USA, LLC$395
  • GSK$339
  • AbbVie$262
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$3,956100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,962 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$13,828
Medicare patients
46
Services billed
223

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide46$83,525
JardianceEmpagliflozin61$75,737
OzempicSemaglutide31$64,524
Synjardy XrEmpagliflozin/Metformin Hcl30$40,640
FarxigaDapagliflozin Propanediol22$29,182
Xigduo XrDapaglifloz Propaned/Metformin12$16,596
XareltoRivaroxaban13$13,941
ShingrixVaricella-Zoster Ge/As01b/Pf56$12,414
Tresiba Flextouch U-200Insulin Degludec12$11,907
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen246$10,325
Lurasidone Hcl16$9,437
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$5,596
SymbicortBudesonide/Formoterol Fumarate11$5,595
Combivent RespimatIpratropium/Albuterol Sulfate11$5,524
Gabapentin84$3,149

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat, Combivent Respimat$236$127,497114 claims
Lilly USA, LLCTrulicity$395$83,52546 claims
Novo NordiskOzempic$237$64,52431 claims
AstraZenecaFarxiga, Symbicort$537$34,77733 claims
Johnson & JohnsonXarelto$241$13,94113 claims
GSKShingrix$339$12,41456 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →